Expert Review of Pharmacoeconomics and Outcomes Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Impact of Under-investment on health in Southern and Central Eastern European Countries
Expert Rev Pharmacoecon Outcomes Res. 2023 Oct 5. doi: 10.1080/14737167.2023.2267766. Online ahead of print.ABSTRACTINTRODUCTION: Better health improves human capital and is a driver to economic growth. The allocation of resources to national health systems should be prioritized as investment and not expense/cost.AREAS COVERED: The purpose of this paper is to investigate the impact of Underinvestment on Medicines and Health in the Southern and Central Eastern European Countries. Two main databases were used for the purpose of this paper. Time series macro data covering the period 1960-2021, and micro data from SHARE survey...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 5, 2023 Category: Health Management Authors: John Yfantopoulos Source Type: research

Inebilizumab for neuromyelitis optica spectrum disorder in Italy: a budget impact model
CONCLUSION: Inebilizumab reduces the INHS expenditure for NMOSD drugs. Future research should explore the cost-effectiveness of inebilizumab vs other NMOSD-targeting drugs in Italy.PMID:37795872 | DOI:10.1080/14737167.2023.2267176 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 5, 2023 Category: Health Management Authors: Carlo Lazzaro Nicola Amedeo Mazzanti Silvia Rossi Fabio Parazzini Source Type: research

Overview and quality assessment of health economic evaluations for homeopathic therapy: an updated systematic review
CONCLUSION: Although results of the CHEC assessment show a positive chronological development, the favorable cost-effectiveness of homeopathic treatments seen in a small number of high-quality studies is undercut by too many examples of methodologically poor research.PMID:37795998 | DOI:10.1080/14737167.2023.2266136 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 5, 2023 Category: Health Management Authors: Thomas Ostermann Julia Burkart Sabine De Jaegere Christa Raak Steven Simoens Source Type: research

Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis
CONCLUSIONS: Sintilimab could be considered the cost-effective second-line strategy for patients with advanced or metastatic squamous non-small-cell lung cancer compared with docetaxel in China.PMID:37789675 | DOI:10.1080/14737167.2023.2267177 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 4, 2023 Category: Health Management Authors: Mochong Liao Shuo Kang Source Type: research

Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?
CONCLUSIONS: The 'Iranian Palbociclib + Fulvestrant' combination was cost-effective in second-line therapy for HR+ HER2- MBC in Iran.PMID:37768209 | DOI:10.1080/14737167.2023.2263167 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 28, 2023 Category: Health Management Authors: Ali Darvishi Ramin Abdi Dezfouli Aliakbar Fazaeli Rajabali Daroudi Narges Zandieh Source Type: research

Willingness to pay for cancer prevention versus treatment in China: implications for cost-effectiveness threshold
CONCLUSION: The findings suggest that though there is a smaller gap between the two scenarios in China as compared to other countries, the WTP may vary under different scenarios. So there's a need to further refine the development of CET by adding parameters like prevention instead of defining one universal threshold.PMID:37754783 | DOI:10.1080/14737167.2023.2262141 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2023 Category: Health Management Authors: Zixuan Zhao Yi Yang Weijia Wu Hengjin Dong Source Type: research

Evaluating high-cost technologies - no need to throw the baby out with the bathwater
Expert Rev Pharmacoecon Outcomes Res. 2023 Sep 27:1-7. doi: 10.1080/14737167.2023.2263647. Online ahead of print.ABSTRACTINTRODUCTION: Evidence generation for the health technology assessment (HTA) of a new technology is a long and expensive process with no guarantees that the health technology will be adopted and implemented into a health-care system. This would suggest that there is a greater risk of failure for a company developing a high-cost technology and therefore incentives (such as increasing the funding available for research or additional market exclusivity) may be needed to encourage development of such technol...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2023 Category: Health Management Authors: Gurdeep S Sagoo Tomos Robinson Diarmuid Coughlan Nick Meader Stephen Rice Luke Vale Source Type: research

Willingness to pay for cancer prevention versus treatment in China: Implications for cost-effectiveness threshold
CONCLUSION: The findings suggest that though there is a smaller gap between the two scenarios in China as compared to other countries, the WTP may vary under different scenarios. So there's a need to further refine the development of CET by adding parameters like prevention instead of defining one universal threshold.PMID:37754783 | DOI:10.1080/14737167.2023.2262141 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2023 Category: Health Management Authors: Zixuan Zhao Yi Yang Weijia Wu Hengjin Dong Source Type: research